International Clinical Trial: Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy with Pembrolizumab and Irinotecan in Patients with Metastatic or Recurrent Malignant Melanoma

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (KCT0012582) titled 'Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy with Pembrolizumab and Irinotecan in Patients with Metastatic or Recurrent Malignant Melanoma' on Sept. 8.

Study Type: Interventional Study

Study Design: Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable

Primary Sponsor: Yonsei University Health System, Severance Hospital

Condition:

Neoplasms

Intervention: Drug : Subjects will receive combination therapy with pembrolizumab and irinotecan for up to 35 cycles (approximately 2 years) until the occurrence of unacce...